Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 6/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 6/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20545835 | 0.78 | HSD17B1 (0.38) | FFAR1HSD17B2HSD17B1CTSA | |
| SCHEMBL20546431 | 0.77 | FFAR1 (0.51) | FFAR1HDAC6HSD17B2HSD17B1PTPN1 | |
| SCHEMBL20546435 | 0.77 | FFAR1 (0.51) | FFAR1HDAC6HSD17B2HSD17B1PTPN1 | |
| SCHEMBL20545943 | 0.75 | CTSA (0.42) | FFAR1HDAC6CTSAMME | |
| SCHEMBL20545881 | 0.75 | CTSA (0.37) | HSD17B2HSD17B1CNR1CTSA | |
| SCHEMBL20545785 | 0.73 | FFAR1 (0.45) | FFAR1CTSA | |
| SCHEMBL20546937 | 0.72 | ALOX5 (0.45) | FFAR1HSD17B2 | |
| SCHEMBL29113436 | 0.72 | ALOX5 (0.45) | FFAR1HSD17B2 | |
| SCHEMBL29219810 | 0.72 | ALDH1A1 (0.42) | HDAC6HSD17B2HSD17B1PTPN1CNR1 | |
| SCHEMBL28368119 | 0.72 | HSD17B2 (0.42) | FFAR1HDAC6HSD17B2HSD17B1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGB3, ITGA1, ITGB5 | FFAR1 37/4885HDAC6 317/4885HSD17B2 2347/4885 |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | ITGB3, ITGA1, ITGB5 | FFAR1 37/4885HDAC6 317/4885HSD17B2 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.